Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Lactate and the Mechanism of Hypoglycemia-Associated Autonomic Failure in Diabetes

  1. Ana María Arbeláez1 and
  2. Philip E. Cryer2⇑
  1. 1Division of Endocrinology and Diabetes of the Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri
  2. 2Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
  1. Corresponding author: Philip E. Cryer, pcryer{at}wustl.edu.
Diabetes 2013 Dec; 62(12): 3999-4001. https://doi.org/10.2337/db13-1360
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Iatrogenic hypoglycemia is a problem for many people with diabetes (1). It causes recurrent morbidity in most people with type 1 diabetes and many with advanced type 2 diabetes and is sometimes fatal. It generally precludes maintenance of euglycemia over a lifetime of diabetes and therefore full realization of the benefits of glycemic control. It impairs defenses against subsequent falling plasma glucose concentrations and causes a vicious cycle of recurrent hypoglycemia.

Hypoglycemia in diabetes is typically the result of the interplay of therapeutic insulin excess—caused by treatment with insulin, a sulfonylurea, or a glinide—and compromised physiological and behavioral defenses against falling plasma glucose concentrations (1,2). Compromised physiological defenses include loss of the normal decrease in β-cell insulin secretion and increase in α-cell glucagon secretion and attenuation of the normal increase in adrenomedullary epinephrine secretion during hypoglycemia. The compromised behavioral defense is failure to ingest carbohydrates because of loss of symptoms due to attenuation of the normal increase in sympathoadrenal, largely sympathetic neural, activity. The concept of hypoglycemia-associated autonomic failure (HAAF) in diabetes posits that recent antecedent hypoglycemia (or sleep or prior exercise) causes both defective glucose counterregulation (by attenuating the epinephrine response in the setting of absent insulin and glucagon responses) and impaired awareness of hypoglycemia (by attenuating sympathoadrenal and the resulting symptomatic responses) and thus a vicious cycle of recurrent hypoglycemia.

Although additional intraislet mechanisms may be involved, it is reasonable to attribute both loss of the insulin and of the glucagon responses to hypoglycemia, the prerequisites to HAAF, to β-cell failure. Insulin normally restrains glucagon secretion and a decrease in insulin normally stimulates glucagon secretion during hypoglycemia. In the setting of absolute endogenous insulin deficiency—β-cell failure—there is no decrease in insulin and thus no increase in glucagon during hypoglycemia (2). However, the mechanism of the attenuated, central nervous system–mediated sympathoadrenal response to falling glucose levels (the key feature of HAAF) is not known. The systemic mediator, brain fuel transport, brain metabolism, and cerebral network hypotheses, which are not mutually exclusive, have been reviewed (2).

Although the precise mechanisms are far from clear (2), one focus is on the glucose metabolite lactate. Cerebral lactate uptake is a direct function of arterial lactate concentrations (3). Many of the studies summarized in this article involved infusions of lactate that raised plasma lactate concentrations to levels that occur only during exercise in humans (3). In addition, the methods involve some technical assumptions (4). Finally, several of the studies were conducted under hyperinsulinemic conditions, and insulin raises plasma lactate concentrations (5).

Lactate infusions resulting in approximately two- to fourfold plasma lactate elevations have been shown to reduce the epinephrine response to, and symptoms of, hypoglycemia in nondiabetic and diabetic humans (6–8). They also shift glycemic thresholds for these responses to lower plasma glucose concentrations (6,7) and cause brain lactate uptake (9,10). Arteriovenous measurements have revealed lactate release from the brain in the euglycemic state and either no brain lactate uptake (11) or brain lactate uptake sufficient to compensate for only about 25% of the calculated brain glucose energy deficit (12) during hypoglycemia in nondiabetic humans.

During insulin infusions that lowered plasma glucose concentrations to approximately 3.6 mmol/L in nondiabetic subjects and approximately 3.2 mmol/L in patients with type 1 diabetes and using [3-13C]lactate nuclear magnetic resonance (NMR) spectroscopy, De Feyter et al. (13) found that [3-13C]lactate infusions increased brain lactate, with no increase in brain oxidation of blood-borne lactate, to a greater extent in the patients. Aside from evidence that some of the five patients may have had impaired awareness of hypoglycemia, it is unclear whether HAAF was present or not. Plasma epinephrine and glucagon concentrations were similar in the two groups. This interesting lactate-related observation did not provide clear insight into the mechanism of the attenuated sympathoadrenal response to a given level of hypoglycemia that characterizes HAAF.

[3-13C]Lactate NMR spectroscopy studies performed in nondiabetic rats by Herzog et al. (14) showed that exposure to recurrent hypoglycemia led to changes in brain metabolism such that increments in circulating lactate allowed the brain to function normally during subsequent hypoglycemia at a plasma glucose concentration of 2.5 mmol/L. Those changes included increased lactate flux through the brain, with only a small increase in brain lactate metabolism, following recurrent hypoglycemia compared with control studies in animals not subjected to prior hypoglycemia. But there was maintenance of brain glucose metabolism following recurrent hypoglycemia, perhaps signaled by increased lactate flux. The mechanism of the lactate effect to maintain brain glucose metabolism is not known, nor is it clear how it might relate to the mechanism of HAAF. Recurrent hypoglycemia is known to reduce the plasma epinephrine response to subsequent hypoglycemia—to produce a model of HAAF (15). It might be reasoned that a decrease in brain glucose metabolism at a plasma glucose concentration of 2.5 mmol/L, as occurred in the control animals in this study (those not subjected to prior recurrent hypoglycemia), signals a sympathoadrenal response. Correspondingly little or no decrease in brain glucose metabolism, as occurred in the experimental animals in this study (those subjected to prior recurrent hypoglycemia), does not signal a sympathoadrenal response. But this reasoning would be flawed. Neuroendocrine, including epinephrine, responses to falling plasma glucose concentrations are signaling events that are not caused by a decrease in whole-brain glucose metabolism (16). These responses occur at higher plasma glucose concentrations than those required to decrease the whole brain cerebral metabolic rate of glucose as measured with [1-11C]glucose positron emission tomography in humans (16). Those higher plasma glucose levels—that do not decrease brain glucose metabolism—not only activate sympathoadrenal responses but also shift the glycemic thresholds for neuroendocrine responses to subsequent hypoglycemia to lower plasma glucose concentrations (17–19). The latter is a key cause of HAAF (2). It does not require a decrease in brain glucose metabolism.

In this issue, Chan et al. (20) report that direct application of lactate to the ventromedial hypothalamus (VMH) in rats increased VMH γ-aminobutyric acid (GABA) levels by about 10-fold and suppressed epinephrine (and glucagon) responses to hypoglycemia. Furthermore, VMH inhibition of lactate transport and of its utilization prevented the lactate-induced rise in VMH GABA; these and antagonism of GABA receptors increased epinephrine (and glucagon) responses to hypoglycemia. Finally, the authors observed that inhibition of lactate transport and utilization lowered elevated VMH GABA and increased epinephrine (and glucagon) responses during hypoglycemia in both prior recurrent hypoglycemia nondiabetic animals and in diabetic animals. While the effect of application of lactate to the VMH to increase VMH GABA could be pharmacologic, the latter findings suggest a physiologic effect of lactate. Given these authors’ previous evidence that GABAergic tone within the VMH contributes to glucose counterregulatory failure in both prior recurrent hypoglycemia nondiabetic (21) and diabetic (22) animal models of HAAF, these interesting data suggest that lactate might suppress glucose counterregulation by increasing VMH GABA. Notably, however, VMH lactate concentrations were not significantly higher in the recurrent hypoglycemic or diabetic animals. The authors discuss their findings largely in the context of lactate as an alternative fuel to glucose despite the finding that increased brain lactate is not metabolized (13,14) but serves as a signaling molecule to maintain brain glucose metabolism (14). They postulate different mechanisms of the putative lactate effect in the recurrent hypoglycemia and diabetic models.

Even in the aggregate, these data do not lead to a simple mechanism of the key feature of HAAF. Nonetheless, the application of sophisticated methods by knowledgeable investigators continues to provide insight into a potential role of lactate (Fig. 1).

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

General mechanism of HAAF in diabetes (right) (1,2) with a potential role of lactate in its pathogenesis (left). ↓, decreased; ↑, increased.

ACKNOWLEDGMENTS

This work was supported, in part, by an American Diabetes Association Mentor-Based Postdoctoral Fellowship Award (7-09-MN-10) and an American Diabetes Association Clinical/Translational Research Award (1-11-CT-14) to P.E.C. A.M.A. is supported, in part, by a Harold Amos Medical Faculty Award.

P.E.C. has served as a consultant to Novo Nordisk and Merck. No other potential conflicts of interest relevant to this article were reported.

The authors thank Janet Dedeke, Washington University, for her help in preparing the manuscript.

Footnotes

  • See accompanying original article, p. 4239.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Cryer PE
    . Hypoglycemia in Diabetes. 2nd ed. Alexandria, VA, American Diabetes Association, 2012
  2. ↵
    1. Cryer PE
    . Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013;369:362–372pmid:23883381
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Rasmussen P,
    2. Wyss MT,
    3. Lundby C
    . Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans. FASEB J 2011;25:2865–2873pmid:21602451
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Henderson GC
    . The diabetic brain during hypoglycemia: in the midst of plenty of lactate. Diabetes 2013;62:3024–3026pmid:23970524
    OpenUrlFREE Full Text
  5. ↵
    1. Cooperberg BA,
    2. Cryer PE
    . Insulin reciprocally regulates glucagon secretion in humans. Diabetes 2010;59:2936–2940pmid:20811038
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Veneman T,
    2. Mitrakou A,
    3. Mokan M,
    4. Cryer P,
    5. Gerich J
    . Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 1994;43:1311–1317pmid:7926305
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Maran A,
    2. Cranston I,
    3. Lomas J,
    4. Macdonald I,
    5. Amiel SA
    . Protection by lactate of cerebral function during hypoglycaemia. Lancet 1994;343:16–20pmid:7905041
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Maran A,
    2. Crepaldi C,
    3. Trupiani S,
    4. et al
    . Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and type I diabetic subjects. Diabetologia 2000;43:733–741pmid:10907119
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. van Hall G,
    2. Strømstad M,
    3. Rasmussen P,
    4. et al
    . Blood lactate is an important energy source for the human brain. J Cereb Blood Flow Metab 2009;29:1121–1129pmid:19337275
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Boumezbeur F,
    2. Petersen KF,
    3. Cline GW,
    4. et al
    . The contribution of blood lactate to brain energy metabolism in humans measured by dynamic 13C nuclear magnetic resonance spectroscopy. J Neurosci 2010;30:13983–13991pmid:20962220
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Wahren J,
    2. Ekberg K,
    3. Fernqvist-Forbes E,
    4. Nair S
    . Brain substrate utilisation during acute hypoglycaemia. Diabetologia 1999;42:812–818pmid:10440122
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Lubow JM,
    2. Piñón IG,
    3. Avogaro A,
    4. et al
    . Brain oxygen utilization is unchanged by hypoglycemia in normal humans: lactate, alanine, and leucine uptake are not sufficient to offset energy deficit. Am J Physiol Endocrinol Metab 2006;290:E149–E153pmid:16144821
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. De Feyter HM,
    2. Mason GF,
    3. Shulman GI,
    4. Rothman DL,
    5. Petersen KF
    . Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes 2013;62:3075–3080pmid:23715622
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Herzog RI,
    2. Jiang L,
    3. Herman P,
    4. et al
    . Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia. J Clin Invest 2013;123:1988–1998pmid:23543056
    OpenUrlCrossRefPubMed
  15. ↵
    1. Powell AM,
    2. Sherwin RS,
    3. Shulman GI
    . Impaired hormonal responses to hypoglycemia in spontaneously diabetic and recurrently hypoglycemic rats. Reversibility and stimulus specificity of the deficits. J Clin Invest 1993;92:2667–2674pmid:8254023
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Antenor-Dorsey JV,
    2. Khoury N,
    3. Su Y,
    4. et al
    . The adrenomedullary epinephrine response to declining plasma glucose concentrations is a signaling event that is not caused by a decrease in the cerebral metabolic rate of glucose [abstract]. Diabetes 2013;62(Suppl. 1):A100
    OpenUrl
  17. ↵
    1. Heller SR,
    2. Cryer PE
    . Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991;40:223–226pmid:1991573
    OpenUrlAbstract/FREE Full Text
    1. Dagogo-Jack SE,
    2. Craft S,
    3. Cryer PE
    . Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993;91:819–828pmid:8450063
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Davis SN,
    2. Shavers C,
    3. Mosqueda-Garcia R,
    4. Costa F
    . Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 1997;46:1328–1335pmid:9231658
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chan O,
    2. Paranjape SA,
    3. Horblitt A,
    4. Zhu W,
    5. Sherwin RS
    . Lactate-induced release of GABA in the ventromedial hypothalamus contributes to counterregulatory failure in recurrent hypoglycemia and diabetes. Diabetes 2013;62:4239–4246pmid:23939392
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Chan O,
    2. Cheng H,
    3. Herzog R,
    4. et al
    . Increased GABAergic tone in the ventromedial hypothalamus contributes to suppression of counterregulatory responses after antecedent hypoglycemia. Diabetes 2008;57:1363–1370pmid:18375441
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Chan O,
    2. Paranjape S,
    3. Czyzyk D,
    4. et al
    . Increased GABAergic output in the ventromedial hypothalamus contributes to impaired hypoglycemic counterregulation in diabetic rats. Diabetes 2011;60:1582–1589pmid:21411513
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes: 62 (12)

In this Issue

December 2013, 62(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lactate and the Mechanism of Hypoglycemia-Associated Autonomic Failure in Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Lactate and the Mechanism of Hypoglycemia-Associated Autonomic Failure in Diabetes
Ana María Arbeláez, Philip E. Cryer
Diabetes Dec 2013, 62 (12) 3999-4001; DOI: 10.2337/db13-1360

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Lactate and the Mechanism of Hypoglycemia-Associated Autonomic Failure in Diabetes
Ana María Arbeláez, Philip E. Cryer
Diabetes Dec 2013, 62 (12) 3999-4001; DOI: 10.2337/db13-1360
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
  • There Is Something About Insulin Granules
  • Metabolic Flexibility of Mitochondria Plays a Key Role in Balancing Glucose and Fatty Acid Metabolism in the Diabetic Heart
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.